Bionano Genomics, Inc. - BNGO STOCK NEWS

Bionano Genomics (BNGO) has pledged financial support to the ACMG Foundation for Genetic and Genomic Medicine's Next Generation Fellowship & Residency Training Awards Program. This initiative aims to address the shortage of qualified medical professionals in genetic and genomic medicine, helping to train new specialists over the next three years. Dr. Max Muenke emphasized the importance of Bionano's commitment, which contributes significantly to expanding the workforce in laboratory genetics. Bionano's President, Erik Holmlin, highlighted the company's mission to improve genome understanding and patient care.

Bionano Genomics (BNGO) has announced a three-year financial commitment to support the ACMG Foundation for Genetic and Genomic Medicine's Next Generation Fellowship & Residency Training Awards Program. This initiative aims to address the shortage of qualified genetic and genomics specialists, providing essential training to new professionals in the field. The ACMGF and its program have been pivotal in enhancing workforce capabilities for over two decades. Bionano's support underscores its commitment to advancing clinical genomics and improving patient access to specialized care.

Bionano Genomics, Inc. (BNGO) reported a record 2022 Symposium with an average daily attendance of 565, a 63% increase from 2021. The event attracted over 4,000 registrants from 82 countries and featured 31 oral presentations and 37 scientific posters focusing on optical genome mapping (OGM). Presentations highlighted OGM's advantages over traditional methods, including higher resolution, faster turnaround, and its ability to detect more structural variants in genetic diseases and cancers. On-demand presentations are available for viewing through the company's website.

Bionano Genomics (BNGO) concluded its 2022 Symposium, showcasing advancements in optical genome mapping (OGM) integrated with next-generation sequencing (NGS). Presentations highlighted the enhanced capabilities of OGM in detecting structural variants (SVs) in various genetic disorders and cancers. Noteworthy findings included improved variant detection in pediatric cancers and myelodysplastic syndromes. Company executives expressed optimism about the future of OGM as a complementary tool for genomic analysis. The online conference center remains accessible for further exploration of the research shared during the event.

Bionano Genomics, Inc. (BNGO) hosted its 2022 Symposium, showcasing the impact of its optical genome mapping (OGM) solutions in cancer research. Key findings from seven presentations emphasized OGM's ability to identify structural variants (SVs) in solid tumors, including pediatric brain tumors and mesothelioma. Dr. Ravindra Kolhe’s ongoing study highlighted OGM's utility over traditional methods, while other studies presented rapid characterization of difficult-to-diagnose tumors. CEO Erik Holmlin noted the growing opportunities for OGM to enhance clinical decision-making and laboratory workflows.

Bionano Genomics (BNGO) announced preliminary Q4 revenue estimates between $5.8 million and $6.2 million, marking a significant increase of 45%-55% over Q4 2020. The company has achieved full-year revenue expectations of approximately $17.5 million to $17.9 million, a growth of 106%-110% compared to 2020. Additionally, it reported a 69% increase in installed systems, totaling 164 by year-end 2021. Bionano exceeded its goals for the year and anticipates strong momentum into 2022, bolstered by advancements in its technologies and clinical trials.

Bionano Genomics (BNGO) recently showcased advancements in optical genome mapping (OGM) at its 2022 Symposium, highlighting its applications in hematologic malignancies. Ten presentations from leading researchers demonstrated OGM's ability to detect structural variants, revealing novel genetic aberrations in conditions like B-cell Chronic Lymphocytic Leukemia (B-CLL) and Acute Lymphoblastic Leukemia (ALL). OGM was noted for being faster and more cost-effective than traditional methods, increasing both accuracy and efficiency in genetic analysis.

Bionano Genomics (BNGO) launched its 2022 Symposium, showcasing the effectiveness of optical genome mapping (OGM) in clinical research for genetic diseases. The event featured six presentations from leading researchers, demonstrating OGM's superior sensitivity, resolution, and efficiency compared to traditional genetic testing methods. Studies revealed high concordance rates of OGM with known chromosomal abnormalities and successful identification of complex structural variants. Moreover, OGM's potential in reproductive medicine was highlighted, showing promise for improving IVF outcomes. 37 posters were presented, with top awards being given in various categories.

Bionano Genomics hosted the first day of its 2022 Symposium, showcasing advancements in optical genome mapping (OGM) for diverse clinical applications. Six presentations highlighted OGM's advantages over traditional methods, demonstrating improved sensitivity and faster results in evaluating genetic diseases. Notable discussions included OGM's role in identifying structural variants and applications in reproductive medicine. The event also honored poster presentations across four categories, emphasizing ongoing research in OGM. The symposium aims to enhance understanding and integration of OGM into clinical practices.